LONDON--(Marketwire - September 02, 2010) -
Genome Research Group (GRG) (PINKSHEETS: KKUR
) recently announced its intended merger with ChromoCure, Inc. and consolidation of the operations and technologies of both groups. Genome Research Group personnel have assumed all executive and board duties and have no current or planned operations in the USA.
The company intends to open permanent offices in the United Kingdom as well as establish the first of several planned research labs and testing partners.
To date, the Company has not been able to secure its previously anticipated investment capital due to the declining USA economy and capital markets. The Company believes it has now secured satisfactory capital commitments and will proceed with its business plan accordingly.
The Company's objectives are:
1. Recapitalize the company's stock structure and change the company's
trading symbol to trade under "Genome Research Group."
2. Establish business offices and permanent address in the United Kingdom
with the most likely location being London.
3. Structure the company's operations as decentralized management with
multiple operational hubs and team members around the world.
4. Secure initial research lab space for the Company's ongoing research and
development for both its cancer imaging systems as well as its
therapeutic protocols and animal modeling experiments.
5. Appoint industry leaders to the Company's Board of Advisors.
6. Partner with cancer labs and pathology labs within the European Union.
The Company does not believe the USA healthcare market will be an open
market inviting of innovation or new ideas. The Company has no immediate
plans to seek partnerships within the USA due to healthcare over-
regulation and control by the US government.
7. Complete and deploy company branding, image, and professional design of
marketing and educational materials.
8. File updated financial information with appropriate legal opinion letter
to achieve "Current" reporting status. The Company has no immediate
intent to become a "SEC Reporting" company due to the massive expense
and liability of that status.
The Company intends to release updates from time to time as these actions are completed.
About Genome Research Group
Genome Research Group develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company's proprietary cancer detection system locates and measures unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's proprietary Therapeutic Modeling Protocols provide statistical modeling and prediction tools for the measurement and monitoring of cancer progression and remission. GRG owns proprietary techniques for non-toxic and non-invasive cancer therapy utilizing hypothermic modulation and resonance.
This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.